The in vitro antibacterial activity of AM-1155 against a wide variety of clinical isolates was compared with those of other fluoroquinolones. The MICs of AM-1155 for 90% of Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis isolates tested were 0.10, 039, and 0.78 ,ug/ml, respectively. The antibacterial activity of AM-1155 Recently, the introduction of both a piperazine side chain and a fluorine atom to the molecule has resulted in the appearance of a new group of fluorinated quinolones such as norfloxacin (10, 11), ofloxacin (17), ciprofloxacin (20), fleroxacin (5), lomefloxacin (7), tosufloxacin (3), and sparfloxacin (12). These new quinolones have high levels of activity against members of the family Enterobacteriaceae and a broad antibacterial spectrum, including Pseudomonas aeruginosa and many gram-positive bacteria.
reference strains maintained in our laboratories and recent clinical isolates collected in various hospitals in Japan between 1984 and 1991.
Determination of MICs. MICs were determined by the twofold serial agar dilution method. The media used for preculture and MIC determinations were Sensitivity Test Broth (Nissui Pharmaceutical, Tokyo, Japan) and Sensitivity Disk Agar-N (SDA; Nissui). For streptococci, preculture took place in brain heart infusion broth (Difco Laboratories, De- troit, Mich.), and MICs were determined by using SDA supplemented with 5% defibrinated horse blood. SDA was supplemented with 5% Fildes enrichment (Difco) for Haemophilus influenzae. Chocolate agar was used for Neisseria gonorrhoeae. Gifu anaerobic medium broth (Nissui) and Gifu anaerobic medium agar (Nissui) were used for obligate anaerobes.
An overnight culture of bacterial suspension was diluted with corresponding fresh broth or buffered saline containing 0.01% gelatin to a concentration of approximately 106 CFU/ ml. A portion (about 5 [LI) of the dilution was inoculated with an inoculation apparatus (Microplanter; Sakuma Seisakusho, Tokyo, Japan) onto agar plates containing various concentrations of drug. The final inoculum size was approximately 104 CFU per spot. The plates were incubated at 37°C for 18 h, but H. infiuenzae and N. gonorrhoeae were cultured in a candle jar for 18 and 48 h, respectively, and anaerobes were incubated in an anaerobic chamber for 18 cocci, and Enterococcus faecalis tested (MIC90s) ranged from 0.10 to 0.78 ,g/ml. This activity was greater than those of norfloxacin, ciprofloxacin, and ofloxacin and was almost the same as those of sparfloxacin and tosufloxacin. The MIC90s of AM-1155 for methicillin-resistant and quinolone-resistant S. aureus were 6.25 and 12.5 ,ug/ml, respectively. Its activity was comparable to those of sparfloxacin and tosufloxacin. All quinolones tested were inactive against E. faecium. The
MIC90s of AM-1155 for members of the family Enterobacteriaceae were less than or equal to 0.39 ,ug/ml except for those for Citrobacter freundii, Providencia rettgeri, and Serratia marcescens, for which they were 1.56, 1.56, and 12.5 p.g/ml, respectively. The MIC90s of AM-1155 for P. aeruginosa, Pseudomonas cepacia, and Xanthomonas maltophilia were 6.25, 12.5, and 1.56 ,ug/ml, respectively. AM-1155 inhibited 90% of Bacteroides fragilis, Clostridium difficile, and Clostridium perfringens strains at concentrations of 3.13, 1.56, and 0.39 ,ug/ml, respectively. H. influenzae was highly susceptible to AM-1155 and tosufloxacin in comparison with its susceptibility to other quinolones. The MIC90s of both compounds for H. influenzae were 0.013 ,ug/ml. AM-1155 showed a high degree of activity against N. gonorrhoeae, as did ciprofloxacin, sparfloxacin, and tosufloxacin. The MIC90s of the four drugs for this species were 0.025 ,ug/ml. The antibacterial activity of AM-1155 was similar to those of sparfloxacin and tosufloxacin and was greater than those of norfloxacin, ciprofloxacin, and ofloxacin against gram-positive bacteria. Against gram-negative bacteria, the antibacterial activity of AM-1 155 was similar to that of sparfloxacin and was slightly less than those of ciprofloxacin and tosufloxacin. Against anaerobes, AM-1155 was the most active quinolone.
The MICs and MBCs of AM-i155 and reference compounds are given in Table 2 . The MBCs of AM-1155 were equal to or twofold greater than the MICs for S. aureus and E. coli and were two-to fourfold greater than the MICs for P. aeruginosa. Similar results were obtained with the other quinolones tested.
Rapid killing was observed in S. aureus Smith, E. coli NIHJ JC-2, and P. aeruginosa GN11189 at one-to fourfold the MIC of AM-1155 (Fig. 1) . AM-1155 reduced the proportion of viable cells of all organisms tested to less than 1% of the inoculum within 2 or 6 h at concentrations equal to the MIC. Against E. coli NIHJ JC-2, the bactericidal activity of AM-1 155 at the MIC was the greatest among the quinolones tested.
The frequency of occurrence of spontaneous mutants resistant to AM-1155, norfloxacin, ciprofloxacin, sparfloxacin, and tosufloxacin was studied. The mutation frequencies in S. aureus Smith, E. coli ML4707, and P. aeruginosa GN11189 at a concentration of two times the MIC of AM-1155 were 2.17 x 10-7, 1.38 x 10-9, and 3.11 x 10-7, respectively. At two The 50% inhibitory concentrations of AM-1155, ciprofloxacin, and sparfloxacin against the gyrase from E. coli KL-16 were 0.64, 1.02, and 0.69 ,ug/ml, respectively (Table 3 ). The 50% inhibitory concentrations of AM-1155, ciprofloxacin, and sparfloxacin against the enzyme from S. aureus SA113 were 10.5, 55.6, and 35.6 ,ug/ml, respectively. The inhibitory activity of AM-1 155 against the gyrase from E. coli KL-16 was similar to those of ciprofloxacin and sparfloxacin. However, AM-1155 inhibited the supercoiling activity of the DNA gyrase purified from S. aureus SAl 13 at a two-to fourfold greater degree than ciprofloxacin and sparfloxacin did.
AM-1155 has a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria and anaerobes. The in vitro antibacterial activities of AM-155 described here are in general agreement with those previously reported for this compound (8) .
Cross-resistance between AM-1155 and ,-lactam antibiotics or aminoglycosides was not observed (data not shown), as reported previously (14) . However, partial cross-resistance was observed between quinolones, as reported previously (2, 9, 18). AM-liSS was bactericidal against organisms in the midlogarithmic growth phase, which is similar to other quinolones. It has been reported that nalidixic acid has a high frequency of mutation and that resistance to nalidixic acid is easily developed (5). However, organisms treated with AM-i155 showed low frequencies of mutation at concentrations of more than two times the MIC for S. aureus, E. coli, and P. aeruginosa. These results were similar to those reported for other quinolones (15).
Sato et al. (16) reported that new quinolones potently inhibit E. coli DNA gyrase with a greater degree of activity than nalidixic acid does. Results of our present study show that AM-1155 inhibits the ATP-dependent supercoiling activity of E. coli and S. aureus SA113 DNA gyrases at concentrations lower than those of ciprofloxacin and sparfloxacin. Although the modes of action of quinolone antimicrobial agents have not been characterized fully, their activities seem to be dependent on the inhibition of DNA gyrase. It seems that AM-1155 inhibits DNA gyrase activity at the same level as the reference quinolones do.
AM-1155 demonstrates good absorption and a good pharmacokinetic profile after oral administration (for a 200-mg dose of AM-1155, the maximum concentration of drug in serum is 1.71 ,ug/ml and the half-life is 7.1 h) (6) . These data suggest that AM-1 155 may have clinical efficacy against urinary tract and systemic infections caused by various bacteria.
